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Calcium channel blocker use and mortality among patients whether cardiac medications can improve clinical out-
with end-stage renal disease. comes for dialysis patients.
Background. Patients on dialysis suffer from alarming rates Among the general population, studies examining cal-of cardiovascular disease. While calcium channel blockers
cium channel blocker (CCB) use have reached mixed(CCBs) are prescribed widely to patients with end-stage renal
conclusions with regard to their effects on patient out-disease (ESRD) for the treatment of hypertension, the long-
term outcomes associated with the use of these medications come [2–8]. Short acting dihydropyridines have been
are not known. We sought to determine the association be- associated with an increased risk of myocardial in-
tween CCB use and mortality among a cohort of ESRD pa- farction, while longer acting CCBs hold mortality riskstients.
similar to other antihypertensive medications. AlthoughMethods. Data were utilized from the United States Renal
calcium channel blockers are prescribed widely to pa-Data System Dialysis Morbidity and Mortality Wave II, a ran-
domly selected prospective cohort of 4065 ESRD patients who tients with ESRD, principally for the treatment of hyper-
began dialysis in 1996. Clinical data, including medication infor- tension, the impact of CCB use on survival has never
mation, were collected 60 days after the start of dialysis. Subse-
been evaluated in this population. CCBs may have differ-quent survival status and cause of death were ascertained.
ent effects in ESRD patients. Chronic renal failureThe Cox proportional hazards model was used to estimate the
relative risk of death associated with CCB use. (CRF) generates a unique biochemical milieu character-
Results. Data from 3716 patients (91.4%) were available for ized by derangements in calcium metabolism. In the set-
analysis. Fifty-one percent of the study patients were prescribed ting of renal failure, calcium channel blockers reverse
a CCB. The use of a CCB was associated with a 21% lower
pathologic levels of intracellular calcium that may con-risk of total mortality (RR 0.79, CI 0.69 to 0.90) and a 26%
tribute to the development of accelerated cardiovascularlower risk of cardiovascular specific mortality (RR 0.74, CI 0.60
to 0.91). For patients with pre-existing cardiovascular disease, disease [9–11]. Therefore, generalization of results from
CCB use was associated with a 23% (RR 0.77, CI 0.65 to 0.91) non-uremic patients to those with renal failure should
and 32% (RR 0.68, CI 0.53 to 0.87) lower risk of total and be done with caution.cardiovascular mortality, respectively.
Based on the experimental benefit of CCBs in uremia,Conclusion. After controlling for known risk factors and
we hypothesized that these medications would be bene-potential confounders, CCBs were found to be associated with
a lower risk of mortality among ESRD patients. ficial to patients with renal failure. We conducted a co-
hort study using data from the United States Renal Data-
base System Dialysis Morbidity and Mortality Study
The risk of cardiovascular disease among patients with Wave II (USRDS DMMS II) to estimate the risk of
end-stage renal disease (ESRD) is 10 times higher than death associated with CCB use among ESRD patients.
the general population [1]. While cardiovascular disease
remains the leading cause of death and disability for
METHODSpatients with renal failure, few studies have investigated
Patient population
Details of the USRDS DMMS II are described inKey words: calcium channel blocker, dialysis, mortality, cardiovascular
disease, hypertension, dihydropyridines, USRDS DMMS II. detail elsewhere [12]. Briefly, the USRDS collects demo-
graphic and clinical data on all patients who have sur-Received for publication May 24, 2001
vived more than 90 days on dialysis. DMMS II was aand in revised form January 10, 2002
Accepted for publication January 11, 2002 prospective study containing a random sample of 4065
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patients initiating dialysis in 1996 and early 1997 from infarction, atherosclerotic heart disease, cardiomyopa-
thy, cerebrovascular accident, cardiac arrhythmia and25% of United States dialysis facilities (N  799). To
obtain comparable numbers of PD and HD patients for cardiac arrest of unknown cause.
the study, PD patients were over sampled. All incident
Statistical analysisPD patients were included whereas only 20% of all HD
The association between baseline CCB use and time topatients were selected. Patients were excluded from
death was analyzed using the Cox proportional hazardsDMMS II if they were younger than 18 years, home
model for censored failure times. In this model, the haz-dialysis patients, or previously transplanted. For the pur-
ard or the instantaneous probability of death, was mod-poses of this analysis, all subjects who participated in
eled as a function of the predictor covariates. The relativeDMMS II were included.
risk (RR) or hazard ratio was then estimated for each
Data collection covariate as the proportionate change in the instanta-
neous probability of death for two individuals differingDialysis center personnel collected baseline and fol-
only by a single unit of that covariate. A relative risk lesslow-up patient data using medical records from dialysis
than one suggests that a one-unit increase in a covariate iscenters, hospitalizations, and personal physicians, and
associated with a longer time to death. Alternatively, aby directly interviewing patients. Dialysis modality was
relative risk greater than one suggests a shorter time todetermined on day 60 of ESRD. Baseline data were
death. Variables used in the multivariate model werecollected 60 days after the start of dialysis. Variables
chosen a priori and retained in the model if there wasused for the purpose of this analysis were patient gender,
biological plausibility or if exploratory analyses sug-age, race (black, white, and other), smoking status
gested that the covariate of interest may be associated(never, former, or current smoker), treatment modality
with death or may confound the relationship between(hemodialysis, peritoneal dialysis, transplant), medica-
CCB use and death. Variables used for adjustment intions, serum albumin, pre-dialysis blood pressure (sys-
the models included age, sex, race, treatment modality,tolic and diastolic), history of diabetes (yes, no), clinical
diabetes, pre-existing cardiovascular disease, undernour-determination of malnourishment (yes, no), and history
ishment, serum albumin, pre-dialysis systolic and dia-of the following specific medical conditions: coronary
stolic blood pressure, and the use of an ACE inhibitor,artery disease, myocardial infarction, coronary angio-
 blocker, and aspirin. Formal tests as well as graphicalplasty, coronary artery bypass surgery, cardiac arrest,
methods were used to verify the existence of propor-and stroke. These clinical conditions, including cardiac
tional hazards. Further, residual diagnostics were used
history, were determined by dialysis personnel through to identify outlying points and to model the correct func-
review of notation in the patients’ medical charts and tional form of adjustment variables. Estimated RR along
through interviews with the patients themselves. A maxi- with corresponding 95% confidence intervals and P val-
mum of 15 medications per patient were recorded. We ues for two-sided tests of association are reported for
determined if CCBs, angiotensin-converting enzyme all regression covariates.
(ACE) inhibitors,  blockers and aspirin had been pre- To improve generalization of our results, patients were
scribed by comparing patients’ recorded medications to not censored at the time of transplant. Since transplant
a list of known generic and brand names. CCBs were patients are generally healthier, censoring patients at the
classified into four groups: group 1, short acting nifedi- time of transplant would have made our results applica-
pine; group 2, long acting dihydropyridines; group 3, ble only to less healthy ESRD patients. Because the
diltiazem; and group 4, verapamil. Changes in treatment dialysis modality administered to a patient can change
modality during follow-up were obtained from the Treat- over time, treatment modality was entered into all analy-
ment History File, which is maintained by the USRDS. ses as a time dependent covariate. The use of the time-
dependent covariate allowed patients to continue to con-Ascertainment of outcome
tribute time at risk for a given modality for the amount
Survival status and cause of death were linked to the of time they underwent that particular modality.
Wave 2 data from the USRDS Patients Standard Analy-
sis File (SAF) via unique patient identifiers assigned
RESULTSby the USRDS. Patient survival status is periodically
updated in the SAF and at the time of analysis was A total of 4065 patients were included in DMMS II.
complete through July 1998. The date and cause of death Of these, 349 patients were excluded from our analysis
listed in the SAF were obtained by the USRDS from because they did not receive a valid USRDS patient
HCFA form #2746, which is completed by the primary identifier, making follow-up impossible. Therefore, 3716
nephrologist following the death of any dialysis patient. patients were available for analysis. There were no nota-
For the purposes of this analysis, death from cardiovascu- ble differences in clinical characteristics between patients
included and excluded from the study.lar disease was defined a priori as death from myocardial
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Table 2. Prevalence of calcium channel blocker use (N  3716)Table 1. Patient characteristics at the time of data collection
No calcium Calcium Calcium channel blocker class N (%)
channel channel
Any calcium channel blocker 1902 (51.2%)blocker use blocker use
Class I 351 (9.5%)Characteristic (N  1814) (N  1902)
Nifedipine (Procardia) 351 (9.5%)
Class II 1162 (31.3%)Age years 59.9 (15.7) 58.2 (15.8)
Female sex 857 (47.2%) 890 (46.8%) Nifedipine (Procardia, Adalat) XL, CC, or GITS 449 (12.1%)
Amlodipine (Norvasc) 637 (17.1%)Race
White 1211 (67.5%) 1147 (60.8%) Felodipine (Plendil) 40 (1.1%)
Isradipine (Dynacirc) 35 (0.9%)Black 450 (25.1%) 567 (30.0%)
Other 134 (7.5%) 173 (9.2%) Nicardipine (Cardene) 10 (0.3%)
Nisoldipine 0 (0%)Smoking status
Never 960 (57.7%) 991 (55.5%) Lacidipine 0 ( 0%)
Class III 363 (9.8%)Former 509 (28.5%) 510 (30.5%)
Current 196 (11.8%) 286 (16.0%) Diltiazem (Cardizem, Dilacor) 363 (9.8%)
Class IV 76 (2.0%)History of cardiovascular diseasea 795 (49.4%) 833 (48.3%)
Undernourished 376 (21.6%) 326 (17.7%) Verapamil (Isoptin) 76 (2.0%)
Combination of 2 classes 50 (1.4%)History of diabetes 874 (49.1%) 951 (50.9%)
Mean serum albumin mg/dL 3.42 (0.58) 3.50 (0.58)
Mean serum cholesterol 188.6 (54.7) 198.4 (56.7)
Mean serum triglycerides 190.5 (145.3) 206.5 (142.1)
Mean pre-dialysis diastolic BP mm Hg 78.5 (11.9) 81.8 (11.9) patients reporting diltiazem use the adjusted relative risk
Mean pre-dialysis systolic BP mm Hg 141.7 (21.1) 150.9 (19.0)
was estimated to be 0.63 (CI 0.49 to 0.81). Of the clinicalAspirin use (yes vs. no) 247 (13.6%) 317 (16.7%)
ACE inhibitor use (yes vs. no) 413 (22.8%) 446 (23.4%) characteristics we studied, advancing age, low serum al-
 blocker use (yes vs. no) 289 (15.9%) 372 (19.6%) bumin, diabetes, pre-existing cardiac disease, and Cauca-
Data are mean (SD) or N (%) sian race were all significantly associated with higher
a Defined as a prior diagnosis of coronary heart disease, coronary artery dis-
risks of total mortality. Blood pressure had a U-shapedease, myocardial infarction, coronary artery bypass surgery, angioplasty, cardiac
arrest, cerebrovascular accident, or congestive heart failure relationship with mortality; pre-dialysis systolic pres-
sures less than 130 and greater than 160 were associated
with a higher risk of death. Similarly, pre-dialysis dia-
The baseline characteristics of the study patients are stolic pressures less than 60 and greater than 90 were
shown in Table 1. Fifty-one percent of our cohort re- associated with a higher risk of mortality. We tested sev-
ported taking a CCB 60 days after the start of dialysis. eral interaction terms, including an interaction between
There were no important differences in baseline clinical CCB use and treatment modality, and an interaction
characteristics between patients who reported using a between CCB use and race. These interaction terms were
CCB, and those who did not. found not to be statistically significant.
Table 2 describes the proportion of patients using Table 4 lists the adjusted and unadjusted relative risks
CCBs stratified by CCB group. The majority of subjects for cardiovascular specific mortality associated with the
prescribed CCBs were receiving long acting dihydropyri- identified baseline characteristics. There were 72.45 car-
dines, particularly amlodipine and long acting nifedipine. diovascular related deaths/1000 person-years among
Diltiazem was prescribed to approximately 10% of the CCB users as compared to 107.75 CV related deaths/
cohort, while verapamil was rarely used. A few patients 1000 person-years among non-users. After adjustment,
(1.4%) reported using a combination of two CCBs. The the use of a  blocker, ACE inhibitor, or aspirin was
most frequent combinations reported were a dihydropyr- not associated with a difference in cardiovascular specific
idine plus diltiazem, followed by a dihydropyridine plus mortality. In contrast, many of the calcium channel
short acting nifedipine. blockers were associated with a significantly lower risk
There were 1232 total deaths during the follow-up of cardiovascular death. For example, the use of any
period. Table 3 presents adjusted and unadjusted relative calcium channel blocker was associated with a 26% lower
risks of total mortality associated with the covariates of risk of cardiovascular specific death (aRR 0.74, CI 0.60
interest. Among CCB users, the total mortality rate was to 0.91). Similarly, the use of the non-dihydropyridine,
169.8 deaths/1000 person-years compared to 225.6 deaths/ diltiazem was associated with 38% lower risk of cardio-
1000 person-years among non-users. The use of a beta- vascular mortality (aRR 0.62, CI 0.42 to 0.90). We did
blocker, aspirin, or an ACE inhibitor was not associated not observe a higher risk of CV mortality associated with
with a difference in the adjusted risk of death from all the prescription of short acting nifedipine. Pre-existing
causes, while the use of a CCB was significantly associ- cardiovascular disease, low serum albumin, undernour-
ated with a lower risk of total mortality. For patients ishment, and diabetes were associated with higher risks
reporting the use of any CCB, the adjusted relative risk of cardiovascular specific death.
for total mortality was 0.79 (CI 0.69 to 0.90) when com- Table 5 illustrates the results of our analysis after strat-
ifying by previous history of cardiovascular disease. Forpared to patients that did not report CCB use, while for
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Table 3. Cox regression results for all-cause mortality
Deaths Unadjusted RR Adjusted RR
Covariate (N1232) (95% CI) P value (95% CI) P value
Age per decade 1225 1.48 (1.42, 1.55) 0.001 1.30 (1.23, 1.38) 0.001
Female sex 601 1.09 (0.97, 1.21) 0.147 1.12 (0.98, 1.29) 0.104
Race
White 897 1.0 1.0
Black 267 0.62 (0.54, 0.71) 0.001 0.74 (0.63, 0.88) 0.001
Other 63 0.48 (0.37, 0.62) 0.001 0.58 (0.43, 0.78) 0.001
Modality
HD 720 1.0 1.0
PD 468 0.96 (0.86, 1.08) 0.550 1.07 (0.92, 1.23) 0.374
Transplant 15 0.17 (0.10, 0.28) 0.001 0.29 (0.15, 0.57) 0.001
Smoking Status
Never 608 1.0 1.0
Former 387 1.28 (1.13, 1.46) 0.001 0.99 (0.85, 1.16) 0.928
Current 142 0.96 (0.80, 1.15) 0.652 1.22 (0.99, 1.51) 0.063
History of CVDa 750 2.79 (2.45, 3.17) 0.001 1.66 (1.42, 1.94) 0.001
Undernourished (yes vs. no) 360 2.19 (1.93, 2.48) 0.001 1.43 (1.23, 1.67) 0.001
History of diabetes 712 1.52 (1.36, 1.70) 0.001 1.31 (1.14, 1.52) 0.001
Albumin 1 g/dL decrease 1126 1.82 (1.67, 2.00) 0.001 1.43 (1.26, 1.62) 0.001
Diastolic BP mm Hg
60 to 90 946 1.0 1.0
Less than 60 132 2.67 (2.23, 3.21) 0.001 1.36 (1.07, 1.74) 0.013
Greater than 90 123 0.55 (0.45, 0.66) 0.001 0.98 (0.77, 1.24) 0.842
Systolic BP mm Hg
130 to 160 564 1.0 1.0
Less than 130 349 1.86 (1.63, 2.13) 0.001 1.53 (1.28, 1.82) 0.001
Greater than 160 288 1.11 (0.96, 1.28) 0.154 1.13 (0.95, 1.33) 0.168
Aspirin (yes vs. no) 234 1.41 (1.22, 1.62) 0.001 0.95 (0.79, 1.13) 0.544
ACE inhibitors (yes vs. no) 270 0.94 (0.82, 1.08) 0.365 0.96 (0.82, 1.13) 0.637
 Blockers (yes vs. no) 207 0.94 (0.81, 1.09) 0.419 1.03 (0.87, 1.22) 0.749
CCB use (yes vs. no) 561 0.74 (0.67, 0.83) 0.001 0.79 (0.69, 0.90) 0.001
No reported use 672 1.0 1.0
Class I 92 0.70 (0.56, 0.87) 0.001 0.73 (0.56, 0.96) 0.022
Class II 340 0.77 (0.68, 0.88) 0.001 0.89 (0.76, 1.04) 0.157
Class III 95 0.71 (0.57, 0.88) 0.002 0.63 (0.49, 0.81) 0.001
Class IV 19 0.72 (0.46, 1.14) 0.163 0.48 (0.24, 0.97) 0.040
Combination of 2 15 0.77 (0.46, 1.29) 0.327 0.65 (0.36, 1.19) 0.165
a Defined as prior Dx of CHD/CAD, MI, bypass, angioplasty, cardiac arrest, cerebrovascular accident or congestive heart failure
patients without a prior history of cardiovascular disease, cause mortality and a 26% lower risk of cardiovascular
specific mortality. After stratifying by history of cardio-the use of a CCB was not associated with a significant
vascular disease, no association was found between CCBchange in the risk of total or cardiovascular related death.
use and mortality for patients without a previous historyIn contrast, a lower risk of mortality was found among
of CVD. In contrast, CCB use was associated with apatients with pre-existing CVD who reported using a
32% lower risk of cardiovascular mortality for patientscalcium channel blocker. After adjustment, the use of
who reported a prior history of CVD.any CCB was associated with a 32% lower risk of death
There was a lower risk of total and cardiovascularfrom cardiovascular disease (aRR 0.68, CI 0.53 to 0.87)
mortality associated with CCB use. While our study de-and a 23% lower risk of death from all causes (aRR
sign is observational, these results are consistent with0.77, CI 0.65 to 0.91). The lowest associated risk was
those from randomized trials among the general popula-observed for the more cardiac selective calcium channel
tion comparing CCBs to placebo for the treatment ofblockers, diltiazem, and verapamil. For patients with a
hypertension [5, 7]. For example, nitrendipine was foundprior history of cardiovascular disease, diltiazem was
to reduce total mortality by 55% versus placebo whenassociated with a 48% lower risk of cardiovascular spe-
prescribed to 492 elderly, hypertensive diabetic patientscific death (aRR 0.52, CI 0.33 to 0.82) and 38% lower
[7]. When felodipine was used as primary therapy torisk of death from all causes (aRR 0.62, CI 0.46 to 0.84).
treat 18,790 hypertensive patients in the Hypertension-
Optimal-Therapy trial, a trend toward decreased cardio-
DISCUSSION vascular mortality was observed as blood pressures were
Greater than half of the ESRD patients under study lowered [5]. We found a lower relative risk of mortality
reported taking a calcium channel blocker. The use of associated with CCB use among our cohort than gener-
ally reported among patients without renal failure. It isany CCB was associated with a 21% lower risk of all-
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Table 4. Cox regression results for CV/stroke-related mortality
Deaths Unadjusted RR Adjusted RR
Covariate (N560) 95% CI P value 95% CI P value
Age per decade 555 1.56 (1.47, 1.67) 0.001 1.35 (1.23, 1.47) 0.001
Female sex 256 0.96 (0.81, 1.14) 0.650 1.03 (0.84, 1.27) 0.756
Race
White 409 1.0 1.0
Black 117 0.60 (0.49, 0.74) 0.001 0.78 (0.61, 1.01) 0.055
Other 31 0.52 (0.36, 0.75) 0.001 0.59 (0.38, 0.92) 0.021
Modality
HD 321 1.0 1.0
PD 229 1.03 (0.87, 1.22) 0.745 1.24 (1.00, 1.53) 0.047
Transplant 3 0.09 (0.03, 0.27) 0.001 0.11 (0.02, 0.74) 0.023
Smoking Status
Never 279 1.0 1.0
Former 185 1.33 (1.10, 1.60) 0.003 0.97 (0.78, 1.21) 0.791
Current 51 0.73 (0.54, 0.98) 0.035 0.93 (0.65, 1.32) 0.682
History of CVDa 295 3.54 (2.89, 4.33) 0.001 1.89 (1.49, 2.41) 0.001
Undernourished (yes vs. no) 146 1.87 (1.55, 2.26) 0.001 1.20 (0.94, 1.52) 0.138
History of diabetes 342 1.73 (1.46, 2.06) 0.001 1.59 (1.28, 1.97) 0.001
Albumin 1 g/dL decrease 515 1.64 (1.43, 1.89) 0.001 1.22 (1.00, 1.48) 0.046
Diastolic BP mm Hg
60 to 90 433 1.0 1.0
Less than 60 69 2.96 (2.29, 3.81) 0.001 1.64 (1.17, 2.31) 0.004
Greater than 90 45 0.44 (0.33, 0.60) 0.001 0.83 (0.56, 1.22) 0.335
Systolic BP mm Hg
130 to 160 245 1.0 1.0
Less than 130 165 2.00 (1.64, 2.44) 0.001 1.58 (1.21, 2.06) 0.001
Greater than 160 137 1.22 (0.99, 1.50) 0.064 1.32 (1.03, 1.69) 0.030
Aspirin (yes vs. no) 125 1.71 (1.40, 2.08) 0.001 1.13 (0.88, 1.44) 0.342
ACE inhibitors (yes vs. no) 121 0.92 (0.75, 1.13) 0.431 0.90 (0.71, 1.14) 0.391
Beta-blockers (yes vs. no) 97 0.97 (0.78, 1.21) 0.804 1.02 (0.79, 1.31) 0.876
CCB use (yes vs. no) 239 0.67 (0.57, 0.79) 0.001 0.74 (0.60, 0.91) 0.004
No reported use 321 1.0 1.0
Class I 39 0.63 (0.45, 0.87) 0.006 0.75 (0.51, 1.11) 0.155
Class II 143 0.68 (0.56, 0.83) 0.001 0.80 (0.63, 1.02) 0.07
Class III 45 0.71 (0.52, 0.97) 0.029 0.62 (0.42, 0.90) 0.013
Class IV 5 0.40 (0.17, 0.97) 0.042 0.27 (0.07, 1.07) 0.063
Combination of 2 7 0.77 (0.36, 1.62) 0.486 0.82 (0.36, 1.85) 0.628
a Defined as prior Dx of CHD/CAD, MI, bypass, angioplasty, cardiac arrest, cerebrovascular accident, or congestive heart failure
Table 5. Cox regression results stratified by history of CVD
No prior history Prior history
Covariate aRRa (95% CI) P value aRRa (95% CI) P value
CV-related mortality
CCB use (yes vs. no) 0.86 (0.58, 1.27) 0.434 0.68 (0.53, 0.87) 0.002
No reported use 1.0 1.0
Class I 1.04 (0.53, 2.05) 0.901 0.65 (0.40, 1.06) 0.085
Class II 0.79 (0.50, 1.25) 0.316 0.78 (0.59, 1.03) 0.078
Class III 0.98 (0.49, 1.93) 0.944 0.52 (0.33, 0.82) 0.005
Class IV 0.44 (0.06, 3.19) 0.413 0.19 (0.03, 1.38) 0.101
Combination of 2 1.06 (0.14, 7.81) 0.953 0.68 (0.28, 1.67) 0.397
All-cause mortality
CCB use (yes vs. no) 0.79 (0.62, 1.01) 0.062 0.77 (0.65, 0.91) 0.002
No reported use 1.0 1.0
Class I 0.96 (0.63, 1.47) 0.856 0.64 (0.45, 0.90) 0.011
Class II 0.81 (0.61, 1.07) 0.137 0.90 (0.75, 1.09) 0.299
Class III 0.65 (0.39, 1.06) 0.082 0.62 (0.46, 0.84) 0.002
Class IV 0.68 (0.25, 1.86) 0.451 0.37 (0.14, 1.00) 0.050
Combination of 2 0.60 (0.15, 2.46) 0.480 0.62 (0.32, 1.21) 0.161
a Adjusted for age, sex, race, treatment modality, smoking status, history of CVD, undernourished, albumin, diastolic BP, systolic BP, aspirin use, ACE inhibitor
use and beta blocker use
possible that the actions of CCBs, such as reduction in In contrast to some reports, which have suggested
that CCBs increase the risk of myocardial infarction andblood pressure, attenuation of left ventricular hypertro-
phy (LVH), and restoration of intracellular calcium are death among selected patient groups when compared
to other antihypertensive agents [3, 6, 8], there was noof particular benefit to patients with ESRD.
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association between the use of a CCB and a greater risk a recent MI [3, 20]. In contrast, our results show a lower
mortality for ESRD patients who reported taking shortof mortality among ESRD patients. Recently published
randomized trials, such as the International Nifedipine acting nifedipine. It is possible that the results of previous
studies do not apply directly to our cohort, either becauseGITS Study and the Nordic Diltiazem Study, have found
similar mortality rates among users of CCBs,  blockers of differences in design or because of differences in the
response of ESRD patients to this medication. Addition-and diuretics [2, 4]. The more gradual reduction in blood
pressure produced by newer, long acting forms of cal- ally, it is possible that complete medication names, such
as XL, GITS, or CC were not accurately reported in thecium channel blockers may account for their enhanced
safety. USRDS, resulting in misclassification and reducing our
ability to detect changes in mortality associated withWe found a particularly strong association between
CCB use and lower mortality among patients with prior short acting nifedipine use.
Our data do not show an association between the usecardiovascular disease (CVD). Studies from the general
population have reached differing conclusions regarding of ACE inhibitors,  blockers, or aspirin and the risk
of mortality among ESRD patients. Patients with renalCCB therapy among patients who have suffered acute
MI [8, 13–17]. The Multi-Center Diltiazem Post In- failure have unique physiologic characteristics, which
may lead to unpredictable responses to traditional car-farction Trial (MDPIT) found no difference in survival
for 2466 patients assigned diltiazem or placebo following diac medications. For example, low renin levels found
in many dialysis patients could attenuate the benefit fromMI [13]. However, subsets of MDPIT subjects, such as
those without pulmonary congestion at presentation and ACE inhibition and explain the lack of association ob-
served between ACE inhibitor use and mortality amongthose with hypertension, experienced a reduction in car-
diac death or re-infarction with diltiazem use [18]. The our cohort. Similarly, the significant platelet dysfunction
induced by renal failure could be responsible for theDanish Verapamil Infarction Trial II (DAVIT II), exam-
ining verapamil therapy following acute MI, found a lack of association detected between aspirin use and
mortality. Finally, a blunted response to sympatheticnon-significant 20% reduction in death or re-infarction
for patients randomized to verapamil versus placebo stimulation might explain a lack of association between
beta-blocker use and mortality among patients with renal[14]. When similar patients from MDPIT and DAVIT II,
with non-Q wave MI and without pulmonary congestion, failure. Further exploration of this complex issue is nec-
essary to optimize antihypertensive therapy among pa-were combined, the relative risk of mortality for users
of diltiazem and verapamil was 0.65 (CI 0.40 to 1.05) tients with ESRD.
Calcium channel blockers possess a variety of poten-[15], similar to our estimates among ESRD patients.
There were no statistically significant associations be- tial therapeutic properties in dialysis patients. Tradi-
tional mechanisms by which CCBs are believed to acttween CCB use and mortality among patients without
prior CVD in our cohort. It is possible that CCBs are include relaxation of vascular smooth muscle, control
of blood pressure, and attenuation of heart rate andof particular benefit for ESRD patients with CVD. Alter-
natively, we may have lacked the statistical power to contractility. These properties may be of special impor-
tance to dialysis patients, who have strikingly high ratesdetect significant associations among patients without
prior CVD because these patients experienced fewer of hypertension and LVH [21, 22]. For example, nifedi-
pine suppresses surges in fibrinogen and von Willebrandevents, though the estimated relative risks associated
with CCB use suggests the former. factor that are produced by erythropoietin therapy [23].
In uremic animals with hypertension, CCBs increase sta-No significant interaction was found between CCB
use, race, and mortality, implying that the lower risk of ble nitric oxide (NOS) metabolites and enhance vascular
NOS activity [24]. Among the general population, CCBsdeath associated with CCB use was similar among white
and African American patients under this study. Among reduce the pathologic changes associated with LVH
[25, 26]. In one study of chronic dialysis patients, diltia-African American patients with hypertension and renal
insufficiency participating in the African American Study zem treatment improved the hemodynamics of LVH, as
measured by echocardiography [27].of Kidney Disease and Hypertension (AASK) trial, the
risk of death was not statistically different among sub- Alternatively, CCBs may be producing beneficial ef-
fects via their specific actions on intracellular calciumjects treated with CCBs as compared to ACE inhibitors
[19]. However, the population studied and end points (iCa) in the setting of renal failure. Pathologic iCa levels
in renal failure have been documented in a variety of cellused for the AASK trial were different from the present
study, limiting direct comparisons. types, including neutrophils, pancreatic islets, platelets,
endothelial cells, and cardiac myocytes [10, 28–30]. Ac-While most studies have found long acting CCBs to
be safe for the treatment of hypertension, short acting companying these changes in iCa are significant abnor-
malities in cell function, including an inability to respondnifedipine was reported to increase the risk of MI for
patients with hypertension, as well as for patients with to signals that use calcium as an intracellular messenger.
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For example, in myocytes, a rise in intracellular calcium Finally, it is possible that there was misclassification
of cause of death. A previous study by Perneger, Klagis associated with impaired response to IGF-1, and de-
creased protein synthesis [29]. The derangement of iCa and Whelton suggested that there is a poor correlation
between cause of death identified on the Death Notifica-produced by renal failure has been linked to elevated
levels of circulating parathyroid hormone, and is normal- tion Form and death certificates [34]. However, 40% of
deaths among patients with ESRD were classified as dueized by parathyroidectomy, and by calcium channel
blockers [11, 31]. CCBs prevent an increase of intracellu- to “renal failure” on their death certificate. Since most
ESRD patients do not die of renal failure per se, thelar calcium by directly antagonizing PTH at the cellular
level, blocking the influx of calcium stimulated by this results of Perneger’s study suggests that the Death Noti-
fication Form may be more accurate than a death certifi-hormone [28, 31–33]. It is possible that CCBs confer a
survival advantage among patients with ESRD by restor- cate. While our study has limitations, it is the first, to
our knowledge, to assess outcomes associated with CCBing levels of iCa.
Our study has several limitations. First, since CCB use use in the ESRD population. In addition, as a population
based study, the results are not a reflection of physician-was assessed at a single point in time, we could not
determine the length of CCB treatment prior to data or region-specific characteristics and therefore can be
collection or whether CCBs were in use at the time of generalized to the entire ESRD population.
death. However, if users and non-users of CCBs were In conclusion, the use of a calcium channel blocker is
equally likely to change medications without respect to associated with lower total and cardiovascular specific
their subsequent mortality status, then non-selective mis- mortality among a cohort of ESRD patients in the
classification of CCB use would occur. This type of mis- USRDS DMMS II. This finding is particularly notable
classification would dilute the association between CCB for patients with a prior history of cardiovascular disease.
use and mortality leading to an underestimation of the Further investigations are needed to confirm these re-
true relative risk. Non-selective misclassification may sults and help guide optimal therapy for this patient
have been a particular problem with aspirin use because population.
patients may not have considered aspirin to be a prescrip-
tion medication. The result would be an underestimation ACKNOWLEDGMENTS
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